Jay Bradner, MD, President, Novartis Institutes for BioMedical Research (NIBR); Executive Committee Member, Novartis and Andrew Plump, President, Research & Development, Takeda Pharmaceuticals

Overview

Many biotech and pharmaceutical companies have rapidly brought teams, platforms and assets to bear on the COVID-19 crisis. In addition, “rival” companies are forging new open-science-inspired collaborations to discover SARS-CoV-2 therapeutics. These two dynamic R&D leaders discuss how their companies are confronting today’s challenges in unexpected ways.

This is part one of a four-part series with Harvard Medical School Executive Education and STAT News